← Back to Search
Mathematical Modelling Of The Role Of Mucosal Vaccine On The Within-host Dynamics Of Chlamydia Trachomatis.
M. D. Akinlotan, D. Mallet, R. Araujo
Published 2020 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
A mathematical model of the within-host replicative dynamics of C. trachomatis infection and its interactions with the immune system, in the presence of a mucosal vaccine, is presented. Our aim is to estimate the requisite efficacy of an efficacious mucosal vaccine that could promote a stable disease-free state in vivo. Sensitivity analysis was used to quantify how variability in the model parameters influence the value of the disease threshold R0. This shows that the two most important factors to be considered for achieving a disease-free state state in vivo, based on their influence on R0, are the efficacy of the Chlamydia vaccine, and the rate at which the humoral immune response protects healthy epithelial cells from infection. Numerical simulations of the model show that a vaccine with a minimum efficacy of 86% may be required for the in vivo control of Chlamydia burden. Such effective but imperfect Chlamydia vaccine could confer long-term protective immunity to genital Chlamydia infections. Conditions under which lower vaccine efficacies may suffice are also explored.
This paper references
Ordinary Differential Equations.
N. G. Parke (1958)
Ordinary Differential Equations.
R. Redheffer (1971)
Stability Analysis of Nonlinear Systems
V. Lakshmikantham (1988)
Interpretation of the Correlation Coefficient: A Basic Review
Richard Taylor (1990)
Azithromycin in the treatment of uncomplicated genital chlamydial infections.
W. Stamm (1991)
A Controlled Trial of a Single Dose of Azithromycin for the Treatment of Chlamydial Urethritis and Cervicitis
David H. Martin (1992)
In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae
A. Ağaçfidan (1993)
Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example
S. Blower (1994)
Cytokine production by epithelial cells 1
A. Stadnyk (1994)
Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies.
G. Comstock (1994)
A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections.
Michael de la Maza (1995)
T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.
X. Yang (1998)
Gamma Interferon Production by Cytotoxic T Lymphocytes Is Required for Resolution of Chlamydia trachomatis Infection
M. Lampe (1998)
The intracellular life of chlamydiae.
M. Hammerschlag (2002)
Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission.
P. van den Driessche (2002)
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?
R. Ribeiro (2002)
T cell responses to Chlamydia trachomatis.
W. P. Loomis (2002)
A mathematical model for the investigation of the Th1 immune response to Chlamydia trachomatis.
D. P. Wilson (2003)
Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
F. Eko (2003)
Mathematical Modelling of Chlamydia
David P. Wilson (2004)
A model of neutralization of Chlamydia trachomatis based on antibody and host cell aggregation on the elementary body surface.
D. P. Wilson (2004)
Use of a quantitative gene expression assay based on micro-array techniques and a mathematical model for the investigation of chlamydial generation time
David P. Wilson (2004)
The chlamydial developmental cycle.
Yasser M. Abdelrahman (2005)
Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine
R. Brunham (2005)
A cellular automata model of tumor-immune system interactions.
D. Mallet (2006)
The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection
P. Horner (2006)
Type III Secretion, Contact-dependent Model for the Intracellular Development of Chlamydia
D. P. Wilson (2006)
Spatial constraints within the chlamydial host cell inclusion predict interrupted development and persistence
A. Hoare (2007)
Live‐attenuated influenza viruses as delivery vectors for Chlamydia vaccines
Q. He (2007)
A novel cellular automata-partial differential equation model for understanding chlamydial infection and ascension of the female genital tract
D. Mallet (2007)
Sampling and sensitivity analyses tools (SaSAT) for computational modelling
A. Hoare (2007)
Sensitivity analysis and parameter estimation for a model of Chlamydia Trachomatis infection
J. Burns (2007)
Epidemiology of chlamydial infection: are we losing ground?
M. Rekart (2008)
Immunity Against Chlamydia trachomatis
E. Marks (2008)
Kinematics of Intracellular Chlamydiae Provide Evidence for Contact-Dependent Development
David P. Wilson (2009)
A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
E. Ekong (2009)
Chlamydial infection and spatial ascension of the female genital tract: a novel hybrid cellular automata and continuum mathematical model.
D. Mallet (2009)
Chlamydia Infection Causes Loss of Pacemaker Cells and Inhibits Oocyte Transport in the Mouse Oviduct1
R. Dixon (2009)
The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
T. Agrawal (2009)
Immunobiological Outcomes of Repeated Chlamydial Infection from Two Models of Within-Host Population Dynamics
D. Vickers (2009)
Role of T lymphocytes in the pathogenesis of Chlamydia disease.
J. Igietseme (2009)
Mathematical Modelling of the Interaction of Chlamydia Trachomatis with the Immune System
Masoumeh Bagher Oskouei (2010)
Dynamic T cell migration program provides resident memory within intestinal epithelium
D. Masopust (2010)
Development of a Chlamydia trachomatis T cell Vaccine
Karuna P. Karunakaran (2010)
Immune Response and Imperfect Vaccine in Malaria Dynamics
Ashrafi M. Niger (2011)
Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial.
J. Schwebke (2011)
Immunopathogenesis in Chlamydia trachomatis Infected Women
M. Mascellino (2011)
Questioning azithromycin for chlamydial infection.
H. Handsfield (2011)
Chlamydia vaccines: recent developments and the role of adjuvants in future formulations
J. Igietseme (2011)
Chlamydia trachomatis infections: screening, diagnosis, and management.
R. Mishori (2012)
Mathematical study of in-host dynamics of Chlamydia trachomatis
O. Sharomi (2012)
Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy
P. Horner (2012)
Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection.
W. Geisler (2013)
Differential Susceptibilities to Azithromycin Treatment of Chlamydial Infection in the Gastrointestinal Tract and Cervix
Laxmi Yeruva (2013)
A cohort study of Chlamydia trachomatis treatment failure in women: a study protocol
J. Hocking (2013)
A Mathematical Model of Chlamydial Infection Incorporating Movement of Chlamydial Particles
D. Mallet (2013)
World Health Organisation. Immunization, Vaccines, and Biologicals
Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity
F. Eko (2014)
Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials.
F. Kong (2014)
The arrested immunity hypothesis in an immunoepidemiological model of Chlamydia transmission.
D. Vickers (2014)
Development status and future prospects for a vaccine against Chlamydia trachomatis infection.
L. Hafner (2014)
Regulatory and public health challenges for vaccines inducing modest efficacy
Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance 2013
World Health Organisation: Report on Global Sexually Transmitted Infection Surveillance 2013
A Chlamydia vaccine on the horizon
R. Brunham (2015)
Treatment of chlamydial infections: 2014 update
S. Kohlhoff (2015)
Development of a vaccine for Chlamydia trachomatis : challenges and current progress
L. Hafner (2015)
A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells
G. Stary (2015)
Target cell limitation constrains chlamydial load in persistent infections: results from mathematical modelling applied to mouse genital tract infection data.
A. Craig (2015)
Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance 2014
Update on Chlamydia trachomatis Vaccinology
L. M. de la Maza (2017)
Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles
Rajnish Sahu (2018)
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
S. Abraham (2019)
Epithelial stratification shapes infection dynamics
C. Murall (2019)
An optimal control model of the treatment of chronic Chlamydia trachomatis infection using a combination treatment with antibiotic and tryptophan
M. D. Akinlotan (2020)